PMID- 31485769
OWN - NLM
STAT- MEDLINE
DCOM- 20191003
LR  - 20210723
IS  - 1432-1335 (Electronic)
IS  - 0171-5216 (Linking)
VI  - 145
IP  - 10
DP  - 2019 Oct
TI  - EP3 receptor is a prognostic factor in TA-MUC1-negative ovarian cancer.
PG  - 2519-2527
LID - 10.1007/s00432-019-03017-8 [doi]
AB  - PURPOSE: Prostaglandin-mediated inflammatory reactions play a major role in 
      different cancers. Recently, it has been observed that prostaglandin E2-receptor 
      3 (EP3) might be an independent prognostic factor for overall survival in 
      cervical and endometrial cancer. The role of EP3 expression in ovarian cancer is 
      currently unknown. METHODS: EP3 expression was analyzed by immunohistochemistry 
      in 156 patient samples using the IR-scoring system. Expression levels were 
      correlated with clinical and pathological parameters and with overall survival 
      (OS) to assess for prognostic relevance. Data analysis was performed using 
      Spearman's correlations, Kruskal-Wallis test and Kaplan-Meier estimates. RESULTS: 
      EP3 expression was significantly higher in clear-cell carcinoma (p < 0.001) 
      compared to the other histological subtypes. No further correlations with 
      clinical parameters could be found. EP3 expression correlated significantly with 
      FSH-receptor expression (p < 0.001), galectin-1 expression in the tumor 
      (p = 0.012) and with cytoplasmatic TA-MUC1 expression (p = 0.001). None of these 
      parameters showed significant correlation with OS. In the TA-MUC1 negative 
      subgroup, EP3 negative patients showed significantly longer OS (median OS: 
      102 months vs. 34 months in EP3 positive patients, p = 0.035), while EP3 did not 
      appear to have prognostic relevance in the TA-MUC1-positive subgroup. CONCLUSION: 
      The potential prognostic relevance of EP3 expression for OS in TA-MUC1 negative 
      patients might reflect an interplay between the COX and the MUC1 pathway, as it 
      has been shown that MUC1 could induce COX2 expression. Our findings support the 
      importance of the prostanoid signaling in TA-MUC1 negative ovarian cancer; 
      however, future studies are necessary to characterize specific pathways and 
      possible interactions.
FAU - Czogalla, Bastian
AU  - Czogalla B
AUID- ORCID: 0000-0001-6589-4736
AD  - Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 
      Marchioninistr. 15, 81377, Munich, Germany.
FAU - Kuhn, Christina
AU  - Kuhn C
AD  - Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 
      Marchioninistr. 15, 81377, Munich, Germany.
FAU - Heublein, Sabine
AU  - Heublein S
AD  - Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 
      Marchioninistr. 15, 81377, Munich, Germany.
AD  - Department of Gynecology and Obstetrics, University of Heidelberg, 69120, 
      Heidelberg, Germany.
FAU - Schmockel, Elisa
AU  - Schmockel E
AD  - Department of Pathology, Ludwig-Maximilians University of Munich, 81337, Munich, 
      Germany.
FAU - Mayr, Doris
AU  - Mayr D
AD  - Department of Pathology, Ludwig-Maximilians University of Munich, 81337, Munich, 
      Germany.
FAU - Kolben, Thomas
AU  - Kolben T
AD  - Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 
      Marchioninistr. 15, 81377, Munich, Germany.
FAU - Trillsch, Fabian
AU  - Trillsch F
AD  - Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 
      Marchioninistr. 15, 81377, Munich, Germany.
FAU - Burges, Alexander
AU  - Burges A
AD  - Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 
      Marchioninistr. 15, 81377, Munich, Germany.
FAU - Mahner, Sven
AU  - Mahner S
AD  - Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 
      Marchioninistr. 15, 81377, Munich, Germany.
FAU - Jeschke, Udo
AU  - Jeschke U
AD  - Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 
      Marchioninistr. 15, 81377, Munich, Germany. udo.jeschke@med.uni-muenchen.de.
FAU - Hester, Anna
AU  - Hester A
AD  - Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 
      Marchioninistr. 15, 81377, Munich, Germany.
LA  - eng
PT  - Journal Article
DEP - 20190904
PL  - Germany
TA  - J Cancer Res Clin Oncol
JT  - Journal of cancer research and clinical oncology
JID - 7902060
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (MUC1 protein, human)
RN  - 0 (Mucin-1)
RN  - 0 (PTGER3 protein, human)
RN  - 0 (Receptors, Prostaglandin E, EP3 Subtype)
SB  - IM
MH  - Biomarkers, Tumor
MH  - Cell Line, Tumor
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - Mucin-1/*metabolism
MH  - Neoplasm Grading
MH  - Neoplasm Metastasis
MH  - Neoplasm Staging
MH  - Ovarian Neoplasms/*metabolism/*mortality/pathology
MH  - Prognosis
MH  - Receptors, Prostaglandin E, EP3 Subtype/*metabolism
MH  - Survival Analysis
OTO - NOTNLM
OT  - EP3
OT  - Gatipotuzumab
OT  - Ovarian cancer
OT  - Prognostic factor
OT  - TA-MUC1
EDAT- 2019/09/06 06:00
MHDA- 2019/10/08 06:00
CRDT- 2019/09/06 06:00
PHST- 2019/08/10 00:00 [received]
PHST- 2019/08/30 00:00 [accepted]
PHST- 2019/09/06 06:00 [pubmed]
PHST- 2019/10/08 06:00 [medline]
PHST- 2019/09/06 06:00 [entrez]
AID - 10.1007/s00432-019-03017-8 [pii]
AID - 10.1007/s00432-019-03017-8 [doi]
PST - ppublish
SO  - J Cancer Res Clin Oncol. 2019 Oct;145(10):2519-2527. doi: 
      10.1007/s00432-019-03017-8. Epub 2019 Sep 4.